A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Miglitol

alpha-Glucosidase Inhibitor class · 1 generic manufacturer · 3 ANDAs filed at FDA.

First FDA approval2021-01-15
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$725,839 in CY2024 Part D spend2K claims · 724 beneficiaries · 329 plans surveyed

Lowest NADAC
$1.75/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.75
Across all dosage forms in distribution.
Highest NADAC
$1.75
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Miglitol used for?

Miglitol is a alpha-Glucosidase Inhibitor medication tracked in Medicare Part D.

Is there a generic for Miglitol?

Yes. 3 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Miglitol?

Across 329 Part D plans, Miglitol averages $1.75/unit (NADAC). Lowest available: $1.75/unit. Highest in distribution: $1.75/unit.

Is Miglitol on the FDA shortage list?

No. Miglitol is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

alpha-Glucosidase Inhibitor1 alternative in D1
01
Acarbose
alpha-Glucosidase Inhibitor
$0.147Lowest NADAC
6Generic mfrs
$9.7MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.